Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
https://www.zacks.com/stock/news/2233984/jazz-jazz-q3-earnings-lag-revenues-in-line-with-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2233984
Feb 29, 2024 - Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
0
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
https://www.zacks.com/stock/news/2247989/why-is-jazz-jazz-up-1-3-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2247989
Mar 29, 2024 - Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
https://www.zacks.com/stock/news/2249176/axsome-axsm-begins-solriamfetol-binge-eating-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249176
Apr 02, 2024 - Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
0
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?
https://www.zacks.com/stock/news/2195599/why-is-jazz-jazz-up-2-6-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2195599
Dec 08, 2023 - Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
https://www.zacks.com/stock/news/2201716/jazz-pharmaceuticals-jazz-ptsd-drug-misses-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201716
Dec 22, 2023 - After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.
0
Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS
https://www.zacks.com/stock/news/2230836/exploring-analyst-estimates-for-jazz-jazz-q4-earnings-beyond-revenue-and-eps?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2230836
Feb 23, 2024 - Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
0
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates
https://www.zacks.com/stock/news/2233401/jazz-pharmaceuticals-jazz-q4-earnings-lag-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233401
Feb 28, 2024 - Jazz (JAZZ) delivered earnings and revenue surprises of -4.56% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
https://www.zacks.com/stock/news/2254013/alkermes-alks-alks-2680-betters-wakefulness-in-phase-ib-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254013
Apr 11, 2024 - Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
0
Pages: 12
<Page 2